LA JOLLA, Calif., Oct. 24 /PRNewswire-FirstCall/ -- Immunosyn Corporation’s CEO, Stephen Ferrone, will make a presentation to brokers and financial institutions at the Financial Services Exchange (FSX) Investment Conference at the Pointe South Mountain Resort in Phoenix, AZ on Thursday, October 25, 2007.
Immunosyn has obtained exclusive worldwide marketing, sales and distribution rights to SF-1019 from its largest shareholder, Argyll Biotechnologies, LLC. Research suggests that SF-1019 has analgesic properties with a perceived ability to substantially reduce the inflammation present in a number of clinical conditions including Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Reflex Sympathetic Dystrophy Syndrome, (RSD or RSDS) and other auto-immune and neurological disorders. The company went public in January of this year and its stock will begin trading on Friday, October 26, 2007.
“Immunosyn is privileged to present to the elite group of brokers and dealers at FSX. We look forward to communicating our company’s objectives and overview as well as to answering questions,” noted Ferrone.
FSX is a premier investment conference organization attended by independent NASD broker/dealer firms. For more than 20 years, FSX has brought these firms together for the purpose of sharing information and showcasing investment opportunities.
About Immunosyn Corporation
La Jolla, CA-headquartered Immunosyn Corporation plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including auto-immune disorders such as Multiple Sclerosis (MS), neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS) and complications from Diabetic Mellitus such Diabetic Neuropathy (DN) and Diabetic Ulcers (DU).
The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements. For additional information, please consult the Company’s most recent public filings and Annual Report on Form 10-K for its most recent fiscal year. The Company assumes no obligation to update the information contained in this press release, whether as a result of new information, future events or otherwise.
blaine@blainegroupinc.com
CONTACT: Bill Kraus, Lisa Baker or Devon Blaine, all of The Blaine Group,
+1-310-360-1499, +1-310-360-1498, FAX, blaine@blainegroupinc.com, for
Immunosyn Corporation